Immunohistochemistry Market - Forecast(2025 - 2031)
Immunohistochemistry Market Overview:
Immunohistochemistry Market Size is valued at $6,207.58 Million by 2031, and is anticipated to grow at a CAGR of 4.85% during the forecast period 2025-2031. The Immunohistochemistry (IHC) market involves the use of antibodies to detect specific antigens in tissue sections through histological techniques, aiding in the diagnosis and research of various diseases, particularly cancer. IHC combines anatomical, immunological, and biochemical methods to visualize the distribution and localization of specific cellular components within tissue samples. This technique plays a crucial role in pathology by enabling precise disease classification, determining prognostic markers, and guiding targeted therapy decisions in clinical settings.
One of the key trends in the IHC market is the rising demand for personalized medicine, particularly in oncology. As precision diagnostics becomes central to cancer treatment, IHC is increasingly used to detect biomarkers that inform individualized therapeutic strategies. Another significant trend is the integration of automation and digital pathology technologies, which enhances workflow efficiency, reproducibility, and data sharing among laboratories and hospitals. These advancements are expanding IHC adoption across both developed and emerging healthcare markets.
Market Snapshot:
Immunohistochemistry Market - Report Coverage:
The “ Immunohistochemistry Market Report - Forecast (2025-2031)” by IndustryARC, covers an in-depth analysis of the following segments in the Immunohistochemistry Market.
COVID-19 / Ukraine Crisis - Impact Analysis:
• The COVID-19 pandemic had a mixed impact on the growth of the Immunohistochemistry (IHC) market. During the initial stages of the pandemic, there was a significant slowdown in diagnostic testing and elective procedures, including cancer biopsies and pathology services, which led to reduced demand for IHC products and services. Many research laboratories and academic institutions faced temporary closures or operational limitations, further dampening the market. However, as the pandemic progressed, the emphasis on healthcare infrastructure, diagnostic capabilities, and disease research began to rebound. The growing focus on biomarker research and immune profiling, particularly in understanding COVID-19 pathogenesis, indirectly supported the application of IHC techniques in virology and immunological studies. Post-pandemic, the market witnessed a resurgence, driven by the restoration of diagnostic services, increased investment in healthcare technologies, and renewed focus on cancer diagnostics and precision medicine, ultimately paving the way for sustained growth in the IHC market.
• The Russia-Ukraine war has significantly impacted the Immunohistochemistry (IHC) market, particularly in Eastern Europe, by disrupting clinical trials, healthcare infrastructure, and supply chains. Both Russia and Ukraine have been important hubs for clinical research, especially in oncology, which heavily relies on IHC techniques. The conflict has led to the suspension of numerous clinical trials, with logistical challenges and patient displacement further complicating research efforts. In Ukraine, the war has devastated hospital systems, reducing services like cancer screening and laboratory testing, which are essential for IHC applications. In Russia, while some pharmaceutical companies continue operations, many have halted new investments and clinical trials, anticipating stricter sanctions and logistical hurdles. These disruptions have not only affected the availability of IHC services but have also led to a projected 90% reduction in international clinical trial activities in Russia over the next three years, impacting the global IHC market growth.
Key Takeaways:
• Antibodies Dominated the Immunohistochemistry Market
On the basis of type, Antibodies held the highest segmental market share of 43% in 2024, due to its fundamental role in disease diagnosis, drug discovery, and research applications. Antibodies, especially primary and secondary types, are central to the IHC process as they specifically bind to antigens in tissue samples, enabling the detection and visualization of target proteins. This makes them indispensable in diagnosing cancers, infectious diseases, and neurological disorders. The increasing prevalence of these conditions has driven demand for high-quality, reliable antibodies. Moreover, continuous advancements in antibody engineering—such as the development of monoclonal, polyclonal, and recombinant antibodies—have improved sensitivity, specificity, and reproducibility in diagnostic assays. The availability of a broad range of antibodies tailored to various biomarkers has further expanded their utility in both clinical and research settings. In February 2025, Leica Biosystems is pleased to announce the launch of two new primary antibodies, PD-L1 and HER2, developed to support cancer research and therapy development. These antibodies, widely used in studying breast, lung, and other cancers, underscore our commitment to empowering pharmaceutical partners with high-quality assays. Also, in April 2025, Avidicure announced its launch with a $50 million seed financing round, led by EQT Life Sciences with participation from Kurma Partners, BioGeneration Ventures, BOM, Curie Capital, and V-Bio Ventures. Avidicure is developing dual agonistic, multifunctional and avidity engineered antibodies, “AVC-Boosters”, that can safely deliver targeted and potent cancer monotherapy. Additionally, pharmaceutical and biotechnology companies heavily rely on antibodies for biomarker validation and companion diagnostics, especially in personalized medicine. These factors, combined with the rising adoption of automated IHC systems that use antibody-based reagents, have solidified the antibodies segment as the dominant force in the IHC market, capturing the largest share globally.
• Diagnostic Leads the Immunohistochemistry Market
On the basis of application, Diagnostic held the highest segmental market share of 77% in 2024 due to its crucial role in the early and accurate detection of a wide range of diseases, particularly cancer. IHC is a gold-standard technique in pathology laboratories for identifying specific antigens in tissue sections, which aids in classifying tumors, determining prognoses, and guiding targeted therapies. The growing global burden of chronic diseases—especially cancer—has significantly increased the demand for precise diagnostic tools, with IHC playing a central role. Ahead of World Cancer Day, the World Health Organization (WHO)’s cancer agency, the International Agency for Research on Cancer (IARC), released the latest estimates of the global burden of cancer. WHO also published survey results from 115 countries, showing a majority of countries do not adequately finance priority cancer and palliative care services, as part of universal health coverage (UHC). Over 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated 20 million cases in 2022. The rapidly growing global cancer burden reflects both population ageing and growth, as well as changes to people’s exposure to risk factors, several of which are associated with socioeconomic development. The segment's dominance is further reinforced by the adoption of IHC in companion diagnostics, where it helps determine patient eligibility for specific therapies, aligning with the rising trend of personalized medicine. Technological advancements such as automated staining systems and improved antibody specificity have enhanced the accuracy, reproducibility, and throughput of diagnostic procedures. Moreover, the integration of IHC into routine clinical workflows and the expanding use of biomarkers in disease stratification have made it an essential diagnostic modality across healthcare systems. These factors collectively explain why the diagnostic segment holds the largest share of the IHC market.
• Growing Demand for Immunohistochemistry Market Due to Rising Prevalence of Cancer and Chronic Diseases
Cancer remains a leading cause of death worldwide, and early, precise diagnosis is critical for improving patient outcomes. IHC plays a vital role in identifying tumor subtypes and specific biomarkers, which are essential for diagnosis, staging, and treatment planning. Beyond oncology, IHC is also valuable in detecting diseases such as cardiovascular disorders, autoimmune conditions, and infectious diseases. As healthcare systems worldwide invest more in diagnostic capabilities, the demand for highly sensitive and specific techniques like IHC is surging. In cancer diagnostics, IHC enables the detection of proteins such as HER2, ER/PR, and Ki-67, which guide treatment decisions and predict prognosis. These applications have elevated IHC from a supportive tool to a frontline diagnostic method. The growing aging population also contributes to the rising burden of chronic illnesses, further increasing the need for efficient diagnostic tools. In 2024, 247,100 Canadians are estimated to hear the words “you have cancer,” compared to the 239,100 new cancer cases in 2023 — an increase that is likely the result of Canada’s growing and aging population. Cancer deaths are also expected to rise this year, from 86,700 in 2023 to 88,100 in 2024. The increase in cancer cases and deaths are expected due to the growing and aging population. In 2024, it is projected that 32,100 people will be diagnosed with lung cancer in Canada. Lung cancer is expected to remain the most common cause of cancer death, accounting for 23.5% of all cancer deaths. Additionally, increased awareness and government initiatives to promote early screening and diagnostics are creating a robust pipeline for IHC test adoption across public and private healthcare facilities. Overall, the global escalation in chronic disease cases, coupled with a rising emphasis on precision diagnostics, positions IHC as an indispensable technology, driving consistent market growth.
• Negative Impact on the Immunohistochemistry Market is Due to High Cost of Instruments and Reagents
A major challenge limiting the widespread adoption of immunohistochemistry (IHC) techniques is the high cost associated with instruments, reagents, and maintenance. IHC requires sophisticated staining systems, high-quality antibodies (both primary and secondary), chromogens, and automated slide processors, all of which carry significant upfront and recurring expenses. In addition, laboratories must invest in trained personnel and regular calibration to ensure consistent diagnostic outcomes. For smaller diagnostic labs, research centers, and facilities in developing nations, these costs can be prohibitive. Budget constraints often compel these institutions to rely on more affordable, less precise diagnostic alternatives. Even in developed markets, the expense of adopting next-generation IHC platforms with advanced automation, digital imaging, and multiplexing capabilities poses a barrier for mid-sized laboratories. Moreover, reagent and antibody costs are continually rising due to supply chain constraints, complex manufacturing processes, and the need for stringent quality control. IHC tests also demand consistency and reproducibility, making low-cost alternatives risky and undesirable. This high cost structure impedes the penetration of IHC technologies in cost-sensitive healthcare settings, slowing market expansion. Furthermore, reimbursement issues, particularly in emerging markets, create uncertainty and may disincentivize providers from offering IHC-based diagnostics.
Key Market Players:
Product launches, approvals, patents and events, acquisitions, partnerships and collaborations are key strategies adopted by players in the Immunohistochemistry Market. The top 10 companies in this industry are listed below:
1. Bio-Rad Laboratories
2. Thermo Fisher Scientific Inc.
3. Merck KGaA
4. Agilent Technologies, Inc.
5. Becton, Dickinson and Company
6. F. Hoffmann-La Roche Ltd.
7. Danaher Corporation
8. Bio-Techne
9. PerkinElmer, Inc.
10. Abcam plc.
Scope of the Report:
Comments
Post a Comment